First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

NCT ID: NCT03401385

Last Updated: 2025-10-21

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 890 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-01-31
• Study Completion Date: 2027-01-01

Brief Summary

This study is one single group of participants with non-small cell lung cancer (NSCLC) who have not been cured by other treatments. It is the first time the drug has been used in humans. There will be two parts and a sub-study.

The primary purpose of the parts are:

• Dose Escalation: To investigate the safety and tolerability and to determine the maximum tolerated dose (MTD) and the recommended dose for expansion (RDE) of DS-1062a
• Dose Expansion: To investigate the safety and tolerability of DS-1062a in additional solid tumors

This study is expected to last approximately 6 years from the time the first participant is enrolled to the time the last subject is off the study. Study sites are located in both the United States and Japan.

The number of treatment cycles is not fixed in this study. Participants who continue to benefit from the study treatment may continue, unless:

• they withdraw
• their disease gets worse
• they experience unacceptable side effects.

The primary purpose of the sub-study is to compare the effectiveness of steroid versus non-steroid mouthwash as prophylaxis against oral mucositis/stomatitis in participants receiving DS-1062a.

The sub-study is a randomized study that will include approximately 76 participants enrolling into the Dose Expansion part.

Detailed Description

The dosage strength will change during the study but all participants will receive the same study drug. So the study is not a true 2-arm study, it is a 2-part study.

In both parts, participants with pathologically documented unresectable advanced NSCLC and triple negative breast cancer (TNBC) who have been refractory to or relapsed from standard treatment or for which no standard treatment is available, will be enrolled. In Dose Expansion, additional indications (hormone receptor [HR]-positive human epidermal growth factor receptor 2 [HER2]-negative breast cancer, HR-positive HER2-low breast cancer, HER2-positive breast cancer, small cell lung cancer [SCLC], endometrial cancer, pancreatic adenocarcinoma, HER2-negative gastric/gastroesophageal junction [GEJ] cancer, esophageal cancer, head and neck squamous cell carcinoma [HNSCC], transitional cell carcinoma of the urothelium, colorectal cancer [CRC], platinum-resistant ovarian cancer, platinum-sensitive ovarian cancer, cervical cancer, and castration-resistant prostate cancer [CRPC]) may be evaluated, if the study treatment demonstrates acceptable safety, tolerability and efficacy in NSCLC participants. After the primary analysis, the main (registered) study will be considered complete, but data will be collected from participants who continue receiving study drug.

In the sub-study, the additional indications listed for Dose Expansion (except for head and neck cancer) may be evaluated.

Conditions

Hormone Receptor Positive Breast Cancer; Triple Negative Breast Cancer; Non-small Cell Lung Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Dose Escalation - All Participants

All participants enrolled in the dose escalation part

Group Type: EXPERIMENTAL

Datopotamab Deruxtecan (Dato-DXd)

Intervention Type: DRUG

A total anti-TROP2 antibody and MAAA-1181a

Dose Expansion - All Participants

All participants enrolled in the dose expansion part

Group Type: EXPERIMENTAL

Datopotamab Deruxtecan (Dato-DXd)

Intervention Type: DRUG

A total anti-TROP2 antibody and MAAA-1181a

Steroid Containing Mouthwash

Intervention Type: DRUG

A mouthwash containing a steroid ingredient administered in sub-study

Non-Steroid Containing Mouthwash

Intervention Type: OTHER

A mouthwash containing a non-steroid ingredient administered in sub-study

Interventions

Datopotamab Deruxtecan (Dato-DXd)

A total anti-TROP2 antibody and MAAA-1181a

Intervention Type: DRUG

Steroid Containing Mouthwash

A mouthwash containing a steroid ingredient administered in sub-study

Intervention Type: DRUG

Non-Steroid Containing Mouthwash

A mouthwash containing a non-steroid ingredient administered in sub-study

Intervention Type: OTHER

Other Intervention Names

DS1062a; Study treatment

Eligibility Criteria

Inclusion Criteria

All Participants:

• Has relapsed or progressed following local standard treatments or for which no standard treatment is available.
• Consents to provide mandatory pre-treatment tumor tissue samples for the measurement of TROP2 and other biomarkers. There is no minimum TROP2 expression level required for inclusion.
• Consents to undergo mandatory on-treatment biopsy if clinically feasible and not contraindicated at the time of on-treatment biopsy, and consents to provide the tumor tissue samples from on-treatment biopsy for the measurement of TROP2 level and other biomarkers.
• Is aged ≥18 years old.
• Has an Eastern Cooperative Oncology Group performance status 0-1.
• Has a left ventricular ejection fraction (LVEF) ≥50% by either an ECHO or MUGA within 28 days before enrollment.
• Has measurable disease based on RECIST version1.1.
• Has adequate bone marrow reserve and organ function within 7 days before Cycle 1, Day 1.
• Has an adequate treatment washout period prior to Cycle 1, Day 1.
• If of reproductive/childbearing potential, agrees to use a highly effective from of contraception or avoid intercourse during and upon completion of the study and for at least 7 months for females and 4 months for males after the last dose of study drug, and agrees not to retrieve, freeze or donate sperm or ova starting at Screening and throughout the study period, and at least 7 months for males and 4 months for males after the final study drug administration.
• After being fully informed about their illness and the investigative nature of the protocol (including foreseeable risks and possible toxicities), is willing and able comply with the protocol and to provide written, ethics committee-approved informed consent form before performance of any study-specific procedures or examinations.
• Has a life expectancy of ≥3 months.
• Has no prior treatment with antibody drug conjugate with deruxtecan (including trastuzumab deruxtecan [T-DXd; DS-8201a], and/or patritumab deruxtecan [HER3-DXd; U3-1402]) and/or ifinatamab deruxtecan [I-DXd; DS-7300]. (Note: Participants in the new HR-positive HER2-low breast cancer cohort is required to have prior treatment with T-DXd and must not have been treated with any other deruxtecan ADC besides T-DXd.)
• Has no prior treatment with trophoblast cell surface antigen 2 (TROP2)-targeted therapy.

• Has a pathologically documented unresectable advanced NSCLC disease not amenable to curative therapy.

• Has a pathologically documented advanced/unresectable or metastatic breast cancer with HR- (estrogen and progesterone receptor) negative disease and HER2 negative expression according to the American Society of Clinical Oncology - College of American Pathologists guidelines (ASCO-CAP).

• Pathologically documented unresectable or metastatic breast cancer that is:

• HER2-negative
• Positive for estrogen receptor and/or progesterone receptor
• Is documented refractory or resistant to endocrine therapy
• Was previously treated with a minimum of 1 and a maximum of 3 prior lines of chemotherapy in the advanced/metastatic setting

• Pathologically documented unresectable or metastatic, and/or extensive-stage SCLC that was previously treated with 1 to 2 prior lines of therapy including platinum-based chemotherapy and immune checkpoint inhibitor.
• No prior exposure to topotecan and/or irinotecan.

• Pathologically documented recurrent or persistent endometrial cancer that relapsed or progressed after any established and/or curative therapies, including at least 1 systemic therapy.

• Pathologically documented unresectable or metastatic pancreatic cancer that was previously treated with at least 1 prior line of systemic therapy in neoadjuvant, adjuvant, locally advanced or metastatic setting.

• Pathologically documented unresectable or metastatic adenocarcinoma of the stomach or esophagus, including the gastroesophagel junction (GEJ) that was previously treated with at least 1 prior line of systemic therapy.
• No known history of HER2-positivity (defined as Immunohistochemistry IHC 3+ or IHC 2+ and in situ hybridization ISH+) as classified by ASCO-CAP at any time.

• Pathologically documented unresectable or metastatic squamous cell carcinoma of the esophagus that was previously treated with at least 1 prior line of therapy including platinum-based chemotherapy.

• Pathologically documented unresectable or metastatic HNSCC that was previously treated with 1-3 prior lines of therapy including platinum and ICI (in combination or sequential), in the advanced or metastatic setting.

• Pathologically documented unresectable, locally advanced or metastatic, urothelial carcinoma (transitional cell and mixed transitional/non-transitional cell histologies) of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra) that was previously treated with at least 1 prior line of therapy including an ICI.

• Pathologically documented unresectable or metastatic CRC that was previously treated with, or were not considered candidates for, available therapies including fluoropyrimidine-based chemotherapy, an anti-vascular. endothelial growth factor therapy, and an anti-epidermal growth factor (EGFR) therapy.
• Has not progressed or relapsed within 6 months of therapy with irinotecan.

• Pathologically documented unresectable or metastatic ovarian cancer that:

• Is epithelial ovarian (including less-common histologies per National Comprehensive Cancer Network (NCCN).
• Has relapsed or progressed within 6 months of platinum-based chemotherapy.

• Pathologically documented unresectable or metastatic ovarian cancer that:

• Is epithelial ovarian (including less-common histologies per NCCN guidelines), fallopian tube, or primary peritoneal presentation.
• Has relapsed or progressed at least 6 months after the most recent platinum-based chemotherapy.

• Pathologically documented unresectable or metastatic cervical cancer that relapsed or progressed after at least 1 prior line of systemic therapy.

• Pathologically documented unresectable CRPC that:

• Is adenocarcinoma of the prostate without neuroendocrine differentiation or small cell histology.
• Is surgically or medically castrated, with testosterone levels of less than 50 nanograms per deciliter.
• Objective progression as determined by radiographic progression for participants with measurable disease after androgen deprivation.
• Has relapsed or progressed after at least 1 of the following: abiraterone, enzalutamide, apalutamide or darolutamide.
• Has at least 1 documented lesion on either a bone scan or a CT/MRI scan.
• CRPC subjects will be chemotherapy-naïve.

• Pathologically documented unresectable or metastatic breast cancer that is:

• HER2-low, defined as IHC 1+ or IHC 2+ / ISH-negative as classified by ASCO-CAP.
• Positive for estrogen receptor and/or progesterone receptor
• Was previously treated with T-DXd in the advanced or metastatic setting

• Is competent and able to comprehend, sign, and date both the main study and the oral mucositis/stomatitis addendum informed consent forms (ICFs) prior to the start of any sub-study procedure or assessment
• Is willing to comply with the procedures of the sub-study, including keeping a daily questionnaire on oral hygiene and oral mucositis/stomatitis-related symptoms

• Uncontrolled or significant cardiac disease including myocardial infarction or uncontrolled/unstable angina within 6 months prior to Cycle 1 Day 1.
• History of congestive heart failure (New York Heart Association classes II-IV) or uncontrolled or significant cardiac arrhythmia, uncontrolled hypertension(resting systolic blood pressure >180 mm Hg or diastolic blood pressure >110 mm Hg).
• Has a mean corrected QT interval (QTcF) prolongation to >470 ms based on of the screening triplicate 12-lead ECGs.
• Has a history of non-infectious interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
• Has clinically significant corneal disease.
• Has an uncontrolled infection requiring IV antibiotics, antivirals, or antifungals. Has active human immunodeficiency virus (HIV) infection that is not well controlled. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA load, CD4+ count >350, no history of AIDS-defining opportunistic infection within the past 12 months, and stable for at least 4 weeks on the same anti-HIV medications. If an HIV infection meets the above criteria, monitoring of viral RNA load and CD4+ count is recommended. Subjects/participants must be tested for HIV during the Screening Period if acceptable by local regulations or an IRB/IEC.
• Has an active or uncontrolled hepatitis B and/or hepatitis C infection.
• Has spinal cord compression or clinically active brain metastases, defined as untreated and symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms. Participants with clinically inactive brain metastases may be included in the study. A minimum of 2 weeks must have elapsed between the end of whole brain radiotherapy and study enrollment. Participants with treated brain metastases that are no longer symptomatic and who require no treatment with steroids may be included in the study if they have recovered from the acute toxic effect of radiotherapy.
• Is lactating or pregnant as confirmed by pregnancy tests performed within 7 days before enrollment.
• Has unresolved toxicities from previous anticancer therapy.
• Has a concomitant medical condition that would increase the risk of toxicity, in the opinion of the Investigator.
• Has a history of severe hypersensitivity reactions to either the drug substances or inactive ingredients of DS-1062a. Has a history of severe hypersensitivity reaction to other monoclonal antibodies.
• Has any other medical conditions, including cardiac disease or psychological disorders, and/or substance abuse that would increase the safety risk to the participant or interfere with participation of the participant or evaluation of the clinical study in the opinion of the Investigator.
• Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder, or any autoimmune, connective tissue or inflammatory disorders with pulmonary involvement, or prior pneumonectomy.
• Has leptomeningeal carcinomatosis.
• Has substance abuse or any other medical conditions such as clinically significant cardiac or psychological conditions, that may, in the opinion of the investigator, interfere with the participant's participation in the clinical study or evaluation of the clinical study results.
• Psychological, social, familial, or geographical factors that would prevent regular follow-up. Adults under guardianship, curatorship, safeguard of justice, or family empowerment measure are not eligible.
• Otherwise considered inappropriate for the study by the investigator.

Exclusion Criteria

• Has had any prior oral mucositis/stomatitis that did not resolve within 3 months of signing the ICFs
• Requires oral steroid or steroid nasal spray or inhaler for asthma, chronic obstructive pulmonary disease, or any other reason at the time of randomization
• Requires immunosuppressive drugs at the time of randomization
• Has oral inflammation or infections, including candidiasis (thrush) at the time of randomization
• Has a history of severe hypersensitivity reactions or any other contraindication to steroids or other active principles or excipients of the mouthwash

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Daiichi Sankyo

INDUSTRY

Sponsor Role: collaborator

AstraZeneca

INDUSTRY

Sponsor Role: collaborator

Daiichi Sankyo Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Global Team Leader

Role: STUDY_DIRECTOR

Daiichi Sankyo

Locations

University of California, Los Angeles

Los Angeles, California, United States

Johns Hopkins Sibley Memorial Hospital

Washington D.C., District of Columbia, United States

Winship Cancer Institute of Emory University

Atlanta, Georgia, United States

Johns Hopkins University

Baltimore, Maryland, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

Tisch Cancer Institute, Icahn School of Medicine

New York, New York, United States

Memorial Sloan-Kettering Cancer Center

New York, New York, United States

Sarah Cannon Research Institute

Nashville, Tennessee, United States

MD Anderson Cancer Center

Houston, Texas, United States

Next Oncology

San Antonio, Texas, United States

START Oncology

San Antonio, Texas, United States

Virginia Cancer Specialists

Fairfax, Virginia, United States

Aichi Cancer Center

Nagoya, Aichi-ken, Japan

The Cancer Institute Hospital of Japanese Foundation For Cancer Research

Koto-Ku, Tokyo, Japan

Showa Medical University Hospital

Shinagawa-Ku, Tokyo, Japan

National Cancer Center Hospital

Chūōku, , Japan

National Cancer Center Hospital East

Kashiwa, , Japan

Countries

United States; Japan

References

Bardia A, Krop IE, Kogawa T, Juric D, Tolcher AW, Hamilton EP, Mukohara T, Lisberg A, Shimizu T, Spira AI, Tsurutani J, Damodaran S, Papadopoulos KP, Greenberg J, Kobayashi F, Zebger-Gong H, Wong R, Kawasaki Y, Nakamura T, Meric-Bernstam F. Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. J Clin Oncol. 2024 Jul 1;42(19):2281-2294. doi: 10.1200/JCO.23.01909. Epub 2024 Apr 23.

Reference Type: DERIVED

PMID: 38652877 (View on PubMed)

Heist RS, Sands J, Bardia A, Shimizu T, Lisberg A, Krop I, Yamamoto N, Kogawa T, Al-Hashimi S, Fung SSM, Galor A, Pisetzky F, Basak P, Lau C, Meric-Bernstam F. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev. 2024 Apr;125:102720. doi: 10.1016/j.ctrv.2024.102720. Epub 2024 Mar 11.

Reference Type: DERIVED

PMID: 38502995 (View on PubMed)

Shimizu T, Sands J, Yoh K, Spira A, Garon EB, Kitazono S, Johnson ML, Meric-Bernstam F, Tolcher AW, Yamamoto N, Greenberg J, Kawasaki Y, Zebger-Gong H, Kobayashi F, Phillips P, Lisberg AE, Heist RS. First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01. J Clin Oncol. 2023 Oct 10;41(29):4678-4687. doi: 10.1200/JCO.23.00059. Epub 2023 Jun 16.

Reference Type: DERIVED

PMID: 37327461 (View on PubMed)

Other Identifiers

173812

Identifier Type: REGISTRY

Identifier Source: secondary_id

DS1062-A-J101

Identifier Type: -

Identifier Source: org_study_id